Clinical Impact of Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease
Insights
Left ventricular diastolic dysfunction (LVDD) is common in chronic kidney disease (CKD), leading to heart failure. Managing CKD complications like LVH and fibrosis is key to improving diastolic function and patient outcomes.
Area of Science:
- Cardiology
- Nephrology
- Biomedical Engineering
Background:
- Left ventricular diastolic dysfunction (LVDD) is prevalent in chronic kidney disease (CKD) patients, often preceding systolic dysfunction.
- LVDD contributes to adverse cardiovascular events, including heart failure and increased mortality in CKD.
- Pathogenesis involves left ventricular hypertrophy (LVH), fibrosis, and elevated left ventricular filling pressures (LVFP) due to CKD-related factors.
Purpose of the Study:
- To summarize the understanding of LVDD in CKD.
- To highlight the role of echocardiography in assessing diastolic function and LVFP.
- To outline current management strategies for LVDD in CKD.
Main Methods:
- Literature review and synthesis of existing research on LVDD in CKD.
- Discussion of echocardiographic parameters, specifically the E/e' ratio, for estimating LVFP.
- Analysis of the multifactorial mechanisms contributing to LVDD in CKD patients.
Main Results:
- LVDD is a significant complication in CKD, linked to poor prognosis.
- Echocardiography, particularly the E/e' ratio, provides a noninvasive method to assess LVFP.
- CKD-associated factors like LVH, inflammation, anemia, and mineral disorders contribute to LVDD.
Conclusions:
- Effective management of LVDD in CKD requires addressing underlying causes such as volume overload and hypertension.
- Preventing myocardial fibrosis and controlling blood pressure are crucial therapeutic goals.
- Early detection and management of LVDD can mitigate risks of heart failure and mortality in CKD patients.
Abstract:
Left ventricular diastolic dysfunction (LVDD) frequently occurs in chronic kidney disease (CKD) and is associated with heart failure and higher mortality. LVDD is observed in patients with early stages of CKD and is associated with cardiovascular events, in patients undergoing incident hemodialysis in the absence of systolic function. The pathogenesis of CKD includes abnormal ventricular filling in diastole and a higher LV filling pressure (LVFP) because of LV hypertrophy (LVH), in addition to myocardial interstitial fibrosis. Therefore, LV dysfunction tends to cause pulmonary congestion. In patients with CKD, the mechanism of LVDD is complicated and mainly involves LVH, which is a physiological response to pressure and volume overload. Other factors related to CKD, including LVH, neurohumoral alterations, inflammation, anemia, and mineral disorders, might cause the development of LVDD. Echocardiography is frequently used for noninvasive evaluation of diastolic function and for estimating LVFP. Echocardiographic quantification of LVFP is based on the E/e' ratio, where E is the early mitral flow velocity on transmitral Doppler and e' is the early mitral annulus velocity obtained from tissue Doppler. An E/e' ratio <8 is considered to be normal, whereas a ratio >15 is considered to mirror the increase in LVFP. The main strategy for treating LVDD is to minimize the large volume shift to control blood pressure and prevent myocardial interstitial fibrosis.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:28Chronic Kidney Disease III: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:29Acute Kidney Injury III: Clinical Manifestations